| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
“Dose dense” chemotherapy in ovarian cancer
|
Vasey, P.A.
|
|
|
15 |
S3 |
p. 226-232
|
artikel
|
| 2 |
Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB–IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial
|
Pujade-Lauraine, E.
|
|
|
15 |
S3 |
p. 222-223
|
artikel
|
| 3 |
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival
|
Kristensen, G.B.
|
|
|
15 |
S3 |
p. 221
|
artikel
|
| 4 |
Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease
|
Zoodsma, M.
|
|
|
15 |
S3 |
p. 282-290
|
artikel
|
| 5 |
Is there still a role for hormonal therapy?
|
Bookman, M.A.
|
|
|
15 |
S3 |
p. 291-297
|
artikel
|
| 6 |
New agents for the treatment of ovarian cancer: the next generation
|
Dupont, J.
|
|
|
15 |
S3 |
p. 252-257
|
artikel
|
| 7 |
New tumor markers: CA125 and beyond
|
Bast JR, R.C.
|
|
|
15 |
S3 |
p. 274-281
|
artikel
|
| 8 |
Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets
|
Boyce, E.A.
|
|
|
15 |
S3 |
p. 266-273
|
artikel
|
| 9 |
Ovarian cancer: is the news good enough?
|
Poveda, A.
|
|
|
15 |
S3 |
p. 298-306
|
artikel
|
| 10 |
Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC
|
Du Bois, A.
|
|
|
15 |
S3 |
p. 224-225
|
artikel
|
| 11 |
Randomized single-agents trials in recurrent epithelial ovarian cancer
|
Sessa, C.
|
|
|
15 |
S3 |
p. 247-251
|
artikel
|
| 12 |
Role of conservative surgery in ovarian cancer: the European experience
|
Colombo, N.
|
|
|
15 |
S3 |
p. 206-211
|
artikel
|
| 13 |
Standard treatment in advanced ovarian cancer in 2005: the state of the art
|
Bookman, M.A.
|
|
|
15 |
S3 |
p. 212-220
|
artikel
|
| 14 |
The role of surgery in recurrent ovarian cancer
|
Pfisterer, J.
|
|
|
15 |
S3 |
p. 195-198
|
artikel
|
| 15 |
Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy
|
González-Martín, A.
|
|
|
15 |
S3 |
p. 241-246
|
artikel
|
| 16 |
Trial design for testing new therapies in ovarian cancer
|
EISENHAUER, E.A.
|
|
|
15 |
S3 |
p. 258-265
|
artikel
|
| 17 |
What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate
|
Monk, B.J.
|
|
|
15 |
S3 |
p. 199-205
|
artikel
|
| 18 |
What is the role of dose-dense therapy?
|
Van Der Burg, M.E.L.
|
|
|
15 |
S3 |
p. 233-240
|
artikel
|
Tijdschrift beschrijving